BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactice to share news the company has agreed to a collaboration with the International Neurorehabilitation Institute in Maryland to perform a clinical trial to assess the capacity of the company’s Red Grape Cell composition to promote eye health. RGC is produced using BioHarvest's Botanical-Synthesis technology. Sobel telling Proactive the study will be an open-label clinical study to evaluate the impact of RGC on multiple sclerosis related optic neuritis driven by inflammation. The Multiple Sclerosis Foundation estimates more than 1 million people in the U.S. and about 2.5 million people worldwide have been diagnosed with MS.
BioHarvest Sciences to begin Human Clinical Study with Multiple Sclerosis-Related Optic Neuritis
